Macrophage Activity in Heart and Leg Artery Disease
Compares immune cells in artery plaques and blood in adults with artery disease.
Key facts
- Who runs it
- Maria Cecilia Hospital
- Where
- Cotignola, ItalySee the site
- Trial code
- Registry title
- Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 18 Mar 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 4 groups
- Treatments tested
- Optical Coherence Tomography assessment
- Record updated
- 14 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease or leg artery disease, such as chronic claudication or critical limb ischemia.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Chronic coronary artery disease, or acute coronary syndrome without ST elevation, or chronic claudication (Rutherford II-III), or critical limb ischemia (Rutherford IV-V).
- Earlier treatment
- People using anti-inflammatory drugs cannot join.
Main reasons for not taking part
- Severe kidney problems
- Severe heart valve disease
- Advanced heart failure
- Advanced liver disease
- Chronic inflammatory or autoimmune disease
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients with chronic coronary artery disease
- Patients with no-ST elevation acute coronary syndrome
- Patients with chronic claudication (Rutherford II-III)
- Patients with critical limb ischemia (Rutherford IV-V)
Who cannot take part
- Use of antinflammatory drugs
- Recent surgical procedures
- Severe valve disease
- Advanced heart failure
- Advanced liver disease
- Chronic inflammatory or autoimmune disease
- Acute infection
- Severe renal dysfunction
Where in Italy
- Maria Cecilia HospitalCotignola, ItalyContact: Roberto Nerla, MD, PhDTaking people
About the trial
What the trial wants to find out
Numerous clinical studies have highlighted the role of macrophages in the destabilization of coronary lesions; however, there is limited literature on the relationship between circulating monocytes and intraplaque macrophages.
Read full original descriptionShow less
This study aims to evaluate and compare the presence of macrophages and their subsequent activation within coronary and peripheral atherosclerotic lesions, and to correlate these findings with the distribution of circulating monocyte subpopulations.
The 4 groups in the trial
- Stable coronary artery diseaseOther group
Treatment: Optical Coherence Tomography assessment
- Acute coronary syndromeOther group
Treatment: Optical Coherence Tomography assessment
- Intermittent claudicationOther group
Treatment: Optical Coherence Tomography assessment
- Critical limb ischemiaOther group
Treatment: Optical Coherence Tomography assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease: the LAST-COP Study
- Plain-language title
- Macrophage Activity in Heart and Leg Artery DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 May 2026